公开(公告)号：US10881659B2

公开(公告)日：2021-01-05

申请号：US14211096

申请日：2014-03-14

Applicant: AbbVie Inc.

Inventor： Kristof Chwalisz ,  Laura A. Williams ,  Rita I. Jain ,  Janine D. North ,  Juki Wing-Keung Ng

IPC: A61K31/513 ,  A61K45/06 ,  A61K31/565 ,  A61K31/57 ,  A61P15/00

Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

公开(公告)号：US20200163965A1

公开(公告)日：2020-05-28

申请号：US16776230

申请日：2020-01-29

Applicant: AbbVie Inc.

Inventor： Kristof Chwalisz ,  Laura A. Williams ,  Rita I. Jain ,  Janine D. North ,  Juki Wing-Keung Ng

IPC: A61K31/513 ,  A61P15/00 ,  A61K31/57 ,  A61K31/565 ,  A61K45/06

Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

公开(公告)号：US20190054027A1

公开(公告)日：2019-02-21

申请号：US16105440

申请日：2018-08-20

Applicant: AbbVie Inc.

Inventor： Yihong Qiu ,  Yuchuan Gong ,  Alexander Ruggles ,  Jared A. Baird ,  Kristof Chwalisz ,  Charlotte D. Owens ,  James W. Thomas ,  Jane Castelli-Haley ,  Keith Gordon ,  Michael C. Snabes ,  Ahmed M. Soliman ,  Oscar Antunez Flores ,  Rita Jain ,  Juki Wing-Keung Ng ,  Janine D. North ,  Hannah Palac ,  Paul M. Peloso ,  Laura A. Williams ,  Hui Zu ,  Yuerong Hu

IPC: A61K9/20 ,  A61K31/513 ,  A61P15/00

Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.